BTX stock forecast
Our latest prediction for BioTime, Inc.'s stock price was made on the Oct. 13, 2017 when the stock price was at 2.66$.
In the short term (2weeks), BTX's stock price should outperform the market by 3.11%. During that period the price should oscillate between -5.41% and +8.24%.
In the medium term (3months), BTX's stock price should outperform the market by 3.91%. During that period the price should oscillate between -12.12% and +20.52%.Get email alerts
About BioTime, Inc.
BioTime, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Alameda, CA.
At the moment the company generates 5M USD in revenues.
On its last earning announcement, the company reported a loss of -0.65$ per share.
The book value per share is 0.80$
Three months stock forecastOct. 13, 2017
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|